TrialGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2024

Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial.

Narikazu Boku et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.